Evidence map›Paper›PMID 42422362›Full record

ArticleFrontiers in physiology2026

CRISPR/Cas9-mediated

Silvia Cardani, Martina Bertocchi, Erika Donà, Filippo Chiesa, Clara Cambria, Ana Lucia Cuadros Gamboa, Eleonora Piscitelli, Vladimir Rancic, Simon Gosgnach, Silvia Pagliardini and 4 more

Abstract read
In one paragraph

Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Silvia CardaniDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Martina BertocchiDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Erika DonàNational Research Council (CNR) - Institute of Neuroscience, Vedano al Lambro, MB, Italy.
Filippo ChiesaDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Clara CambriaDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Ana Lucia Cuadros GamboaDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Eleonora PiscitelliNeuroMi - Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy.
Vladimir RancicDepartment of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Simon GosgnachDepartment of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Silvia PagliardiniDepartment of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Flavia AntonucciDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Diego FornasariDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Simona Di LascioDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.
Roberta BenfanteDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: PHOX2B is a master transcriptional regulator of autonomic nervous system development whose mutations cause neurocristopathies including neuroblastoma and congenital central hypoventilation syndrome (CCHS). However, the identification and functional relevance of PHOX2B target genes remain incompletely defined, partly due to the lack of robust cellular models. Methods: Through CRISPR/Cas9-engineering we established a PHOX2B functional knockout IMR32 neuroblastoma model, and combined transcriptomic, chromatin-binding, electrophysiological, and live-cell imaging analysis to investigate PHOX2B-dependent pathways. We then assessed the developmental relevance of the obtained results in iPSC-derived sympathetic neurons from CCHS patients carrying different PHOX2B mutations. Results: PHOX2B functional knockout (PHOX2B-KO) cells exhibited morphological and molecular features indicative of enhanced neuronal maturation. RNA-seq and ChIP-seq analyses highlighted an unexpected direct role for PHOX2B in regulating the expression of ion channels, including Discussion: Together, our data establish the PHOX2B functional knockout neuroblastoma model as a valuable platform for functional genomics, enabling systematic analysis of PHOX2B targets and highlighting its critical role in coordinating transcriptional programs that shape neuronal excitability and maturation.

Indexed as

ChIP-seqCRISPR/Cas9ion-channels regulationiPSC-derived autonomic neuronsneuroblastomaneuronal excitabilityPHOX2BRNA-seq

Identifiers

PMID42422362
PMCPMC13341513

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.